Strategic acquisitions Zymeworks recently acquired Theravance for $929M, signaling aggressive growth and expanded capabilities which could open cross-sell opportunities for their biotherapeutics portfolio and joint development negotiations with the newly combined entity.

Collaborative partnerships Active and recent partnerships with Gandeeva Therapeutics to leverage cryo-EM driven design, and exclusive rights deals with BeOne Medicines and Jazz Pharmaceuticals for zanidatamab, present multiple co-development and licensing avenues for customers seeking access to differentiated antibody formats.

Diversified pipeline A portfolio focused on multispecific antibodies and antibody-drug conjugates, plus Ziihera HER2-targeted bispecifics, suggests multiple entry points for pharma partners targeting difficult-to-treat cancers and autoimmune conditions, including FRα-targeting ADC programs showcased at industry conferences.

Clinical momentum Active presentation of Phase 1 data and ongoing dose-escalation studies for ZW191 at AACR and other venues indicate near-term clinical milestones that can attract collaborators and licensees seeking evidence of translational potential and risk-sharing opportunities.

Global reach With a global operating footprint, a mid-sized workforce, and engagement in high-profile events and congresses, Zymeworks offers regional partnerships and co-development deals tailored to territories where their platform technology and partnered programs can accelerate market access.